STOCK TITAN
  1. Home
  2. News
  3. KURA

Kura Oncology Inc - KURA STOCK NEWS

Welcome to our dedicated news page for Kura Oncology (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kura Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kura Oncology's position in the market.

News
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Kura Oncology, Inc. (Nasdaq: KURA) granted inducement awards of nonstatutory stock options to three new employees. Each stock option has an exercise price of $21.02 per share and will vest over four years, subject to the employees' continued service relationship with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
-
News
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
Rhea-AI Summary
Kura Oncology, Inc. (Nasdaq: KURA) reported preliminary clinical data from the first 20 patients in KOMET-007, a Phase 1 trial of ziftomenib in combination with standard treatments for acute myeloid leukemia. The data showed a 100% complete remission rate in newly diagnosed patients and encouraging clinical activity in refractory/relapsed patients. The menin inhibitor ziftomenib demonstrated an encouraging safety profile and tolerability, with no differentiation syndrome events reported. The 200 mg dose was cleared, and enrollment at the 400 mg dose is ongoing. Kura plans to initiate a Phase 1b dose validation/expansion in combination with standard treatments in newly diagnosed patients. The company remains in a strong financial position with cash runway expected into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.1%
Tags
none
-
News
Kura Oncology Announces Oversubscribed $150 Million Private Placement
Rhea-AI Summary
Kura Oncology, a clinical-stage biopharmaceutical company, has announced a private placement to sell shares of its common stock and pre-funded warrants, expecting to raise approximately $150 million. The funding comes from existing investors, providing runway into 2027. The company will host a virtual investor event on January 30 to highlight preliminary combination data for ziftomenib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.13%
Tags
none
News
Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
Rhea-AI Summary
Kura Oncology, Inc. (NASDAQ: KURA) announced a clinical collaboration with The Leukemia & Lymphoma Society (LLS) to evaluate Kura’s menin inhibitor, ziftomenib, in combination with chemotherapy in pediatric patients with relapsed/refractory acute leukemia. The collaboration aims to advance more effective, safer treatments with fewer long-term side effects for children with blood cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
clinical trial
-
News
Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit
Rhea-AI Summary
Kura Oncology, Inc. (KURA) announced that its CEO, Troy Wilson, Ph.D., J.D., will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on December 5, 2023. The live webcast will be available on Kura's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences
-
News
Kura Oncology Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Kura Oncology reports Q3 2023 financial results and provides a corporate update. The company expects to complete enrollment in the KOMET-001 trial of ziftomenib by mid-2024. Preliminary data from the KOMET-007 combination trial is anticipated in Q1 2024. The company also announced the initiation of the FIT-001 trial for next-generation FTI, KO-2806. Kura has $452.6 million in cash and investments, providing runway to mid-2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.01%
Tags
earnings
News
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
Rhea-AI Summary
Kura Oncology and Mirati Therapeutics have announced a clinical collaboration and supply agreement to evaluate the combination of KO-2806 and adagrasib in patients with KRASG12C-mutated non-small cell lung cancer. The collaboration aims to address the need for more durable and effective treatment options for advanced solid tumors. Kura will sponsor the Phase 1 study and Mirati will supply adagrasib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.38%
Tags
none
-
News
Kura Oncology to Participate in Three Upcoming Investor Conferences
Rhea-AI Summary
Kura Oncology, Inc. announced that its CEO, Troy Wilson, will participate in three upcoming investor conferences. The conferences include the TD Cowen Fall Oncology Innovation Summit, the Stifel 2023 Healthcare Conference, and the Jefferies London Healthcare Conference. Live audio webcasts will be available on Kura's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
conferences
-
News
Kura Oncology to Report Third Quarter 2023 Financial Results
Rhea-AI Summary
Kura Oncology, Inc. will report its third quarter 2023 financial results on November 2, 2023. A webcast and conference call will be held to discuss the financial results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
conferences earnings
News
Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806
Rhea-AI Summary
Kura Oncology announces the initiation of Phase 1 trial for KO-2806 in the treatment of advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
Stock KURA logo
Kura Oncology Inc

Nasdaq:KURA

KURA Rankings

#2114 Ranked by Market Cap
#4684 Ranked by Stock Gains
N/A Ranked by Dividends

KURA Stock Data

1.48B
48.24M
1.75%
105.55%
13.67%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About KURA

at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.